Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
May 01  •  01:39PM ET
30.27
Dollar change
+12.27
Percentage change
68.19
%
Today, 1:01 PMStrong demand for upsized IPO drives Hemab Therapeutics' 66% first-day surge.
Index
-
P/E
-
EPS (ttm)
-
Insider Own
-
Shs Outstand
1.78M
Perf Week
-
Market Cap
-
Forward P/E
-
EPS next Y
-
Insider Trans
-
Shs Float
-
Perf Month
-
Enterprise Value
-
PEG
-
EPS next Q
-
Inst Own
-
Perf Quarter
-
Income
-
P/S
-
EPS this Y
-
Inst Trans
-
Perf Half Y
-
Sales
-
P/B
-
EPS next Y
-
ROA
-
Perf YTD
-
Book/sh
-
P/C
-
EPS next 5Y
-
ROE
-
52W High
- -
Perf Year
-
Cash/sh
-
P/FCF
-
EPS past 3/5Y
- -
ROIC
-
52W Low
- -
Perf 3Y
-
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
- -
Gross Margin
-
Volatility
- -
Perf 5Y
-
Dividend TTM
-
EV/Sales
-
EPS Y/Y TTM
-
Oper. Margin
-
ATR (14)
4.81
Perf 10Y
-
Dividend Ex-Date
-
Quick Ratio
-
Sales Y/Y TTM
-
Profit Margin
-
RSI (14)
-
Recom
-
Dividend Gr. 3/5Y
- -
Current Ratio
-
EPS Q/Q
-
SMA20
0.00%
Beta
-
Target Price
-
Payout
-
Debt/Eq
-
Sales Q/Q
-
SMA50
0.00%
Rel Volume
-
Prev Close
18.00
Employees
72
LT Debt/Eq
-
Earnings
-
SMA200
0.00%
Avg Volume
-
Price
30.27
IPO
May 01, 2026
Option/Short
No / No
EPS/Sales Surpr.
- -
Trades
Volume
1,863,106
Change
68.19%
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company. It engages in developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. The company was founded on February 12, 2026 and is headquartered in Cambridge, MA.